Summary We examined the importance of dosing interval between leucovonin (LCV) and 5-fluorouracil (5-FU) on intracellular thymidylate synthase (TS) ternary complex. free TS and total TS protein levels in human MCF-7 breast and NCI H630 colon cancer cell lines. A 2-to 3-fold increase in total TS was noted when either cell line was exposed to 5-FU 1OMLm plus LCV (0.01 -10;jM) compared with a 1.4-to 1.6-fold increase in total TS due to 5-FU 1O;IM alone. The amount of TS ternary complex formed was 2-to 3-fold higher in both cell lines treated with the combination of 5-FU and LCV compared with 5-FU alone. TS complex formation and total TS protein increased with LCV dose (O. 1 -1OIM). In MCF-7 cells, the maximal increase in total TS protein and TS ternary complex formation was observed when 5-FU was delayed for 4 h after the start of LCV exposure. In NCI H630 cells, maximal total TS protein and ternary complex formation occurred when 5-FU was delayed for 18 h after the start of LCV exposure. The amount of free TS did not change in either cell line whether 5-FU was given concurrently with LCV or delayed for up to 24 h. The accumulation rate of intracellular folates in the form of higher glutamates Glu,-Glu, was rapid in MCF-7 cells (maximal formation after 4 h). whereas in H630 cells accumulation of higher polyglutamates continued to increase up to 18 h. The time of peak folate polyglutamate (Glu,-Glu,) formation coincided with the time of peak TS complex formation and total TS protein in each cell line. In these human carcinoma cell lines, the LCV dose and interval between 5-FU and LCV play a role in increased TS total protein and TS ternary complex: however, the amount of free TS is independent of the interval between 5-FU and LCV. The timeand dose-dependent increases in TS ternary complex and TS total protein are associated with differences in the accumulation of folate polyglutamates in these cell lines.
The fluoropyrimidine 5-fluorouracil (5-FU) is the single most active agent for the treatment of patients with colorectal cancer and remains one of the most active chemotherapeutic agents used in the treatment of patients with head and neck as well as breast cancer (Moertel, 1978; Grem 1988 Grem . 1990 ). One of the principal mechanisms of action of 5-FU is inhibition of the enzyme thymidylate synthase (TS). TS catalyses the methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) and is critical in de novo pyrimidine nucleotide formation, essential for DNA synthesis (Santi et al.. 1974; Danenberg, 1977) . Fluorodeoxyuridine monophosphate (FdUMP), an active intracellular metabolite of 5-FU, forms a covalent complex with TS in the presence of the folate co-factor 5,10-methylene tetrahydrofolate (5,1O-methylene-H4PteGlu), resulting in intracellular thymidine depletion. Preclinical laboratory studies suggest that the formation of TS ternary complex (TS-FdUMP-5.10-methylene-H4PteGlu) is a critical step for the cytotoxicity of the fluoropyrimidines (Santi et al.. 1974; Heidelberger. 1975; Danenberg, 1977; Hardy et al., 1987) . The stability and amount of ternary complex formed has been shown to be dependent on the concentration of the reduced folate substrate 5,10-methylene-HJtteGlu (Lockshin and Danenberg, 1979) . Leucovorin (LCV; folinic acid, 5-formyltetrahydrofolate) is a reduced folate that, when metabolised intracellularly, increases the intracellular reduced folate pool, including 5,10-methylene-H4PteGlu. This increase in the reduced folate pool results in enhanced formation and stability of TS ternary complex (Houghton et al.. 1981; Mini et al., 1987) .
Several in vitro studies have demonstrated that co-admin- 1978; Keyomarsi and Moran. 1986 : Mini et al.. 1987 : Petrelli et al., 1987 Park et al.. 1988; Moran and Scanlon, 1991) .
These studies suggest that concentrations of LCV in the 1.0 -10JM range are optimal for potentiating the activity of 5-FU in human and non-human cancer cell lines. Intracellular reduced folate pools have been shown to increase with increasing LCV dose; however. LCV concentrations above 1 gM may not further increase 5-FU cytotoxicity (Keyomarsi and Moran, 1986) . The duration of LCV exposure also appears to be an important variable in the interaction of LCV with 5-FU since folate polyglutamation is a time-dependent process and the polyglutamates of 5.10-methyleneH4PteGlu are 50-to 100-fold more potent in ternary complex formation than the monoglutamate forms (Moran and Scanlon, 1991 5-FU (Machover et al.. 1986; Erlichman et al.. 1988 Poon et al.. 1989; Valone et al., 1989 : Advanced Colorectal Cancer Meta-Analysis Project. 1992 . In several randomised trials, the overall response to combination therapy with 5-FU LCV was superior to 5-FU alone for the treatment of patients with advanced colorectal cancer. and in one of these tnrals a small but significant increase in survival was demonstrated (Poon et al.. 1989 ). More recently. it has been shown that treatment with 5-FU plus LCV prolongs disease-free survival and overall survival in patients with Dukes' B and C colorectal cancer (Wolmark et al.. 1993 ). All of these clinical studies have used a vanrety of doses and schedules of LCV; however, the optimal dose and schedule of LCV as a modulator of 5-FU have not been clearly defined.
We have recently descnrbed an immunological assay using TS monoclonal antibodies that can detect and quantitate the amount of TS enzyme that is bound as ternary complex in human tumour cells following treatment with 5-FU or 5-FU LCV (Johnston et al.. 1991; Drake et al.. 1993) . We have applied this assay to detect and quantitate the intracellular amount of ternary complex within cells following treatment with various doses and schedules of LCV. The goal of the present study was to determine the importance of the dose and interval of exposure between LCV and 5-FU on intracellular TS ternary complex formation and TS protein levels in human colon and breast cancer cell lines.
Materials and methods

Cell culture
The characteristics of the human colon cancer cell line NCI H630 and the human breast cancer cell line MCF-7 have been described previously (Soule et al.. 1973; Park et al.. 1987) . Cells were maintained in folate-free minimum essential media (Gibco. Grand Island. NY. USA) supplemented with 50 nM L-leucovorin (Lederle), 10% dialysed fetal calf serum (Gibco) and 2 mm glutamine (Gibco) and grown in 75 cm2 plastic culture flasks (Falcon Labware. Oxnard. CA, USA) at 3TC in a humidified 5% carbon dioxide incubator.
Growth inhibition studies
Equal numbers of MCF-7 and NCI H630 cells (2 x 10'ml) were plated onto 25 cm' flasks (Falcon Labware). After 48 h. cells were treated with either 5-FU or 5-FU plus LCV using the schedule and doses of LCV described in Figure 1 . Cells were harvested 96 h after plating and an aliquot from each flask was counted using a Coulter electronic cell counter (Coulter Electronics. Hialeah. FL. USA).
5-FLE LC treatment schedule
Equal numbers of cells (1 x 10' ml-') from each cell line were plated onto 75 cm' flasks. Forty-eight hours following plating, cells were exposed to 0.1. 1.0. 5.0 and 1O gM LCV for 4 h. After 4 h of LCV exposure. cells were washed twice with 15 ml of phosphate-buffered saline (PBS) and placed in fresh medium. Starting at time point 0. duplicate sets of LCV-treated cells were exposed to 5-FU (10 gM) for 2 h at various intervals, as illustrated in Figure 1 . At the end of the 2 h 5-FU exposure. the cells were washed twice in 15 ml of PBS and placed in fresh medium. Twenty-four hours after 5-FU exposure. cells were harvested from the plates by a 10 min incubation in 3 ml of 0.05% trypsin in 0.05 M EDTA. Cell pellets were collected in 15 ml tubes (Falcon) by centrifugation for 10 min at 1000 g. Pellets were resuspended in washed and reacted with TS 106 antibody (10Lg ml-'). Blots were then overlaid with antimouse secondary antibody (10 iLg ml-') conjugated with horseradish peroxidase (BioRad). Protein bands representing complex and free TS were detected colonrmetrically using 3'.5'-tetramethylbenzidine (TMB) (Figure 2 (Figure 2 ). All measurements of TS ternary complex were performed 24 h after 5-FU exposure. In MCF-7 cells. the maximal TS ternary complex formation occurred when 5-FU was delayed for 4 h after the start of LCV administration (Figure 3a) . This resulted in a 1.8-± 0.2-fold increase in TS ternary complex to free TS ratio over that seen when both drugs were added simultaneously (Figure 3a) . A similar effect was apparent in NCI H630 cells; however, maximal TS ternary complex formation occurred when 5-FU was delayed for 18 h after the start of the 4 h LCV exposure (Figure 3b ). This resulted in a 1.75-± 0.23-fold increase in the ratio of TS ternary complex to free TS over that seen when both drugs were used simultaneously (Figure 3b ). TS ternary complex formation increased with increasing LCV dose (0. 1-10IM) in both MCF-7 and H630 cells; however, the time peak ternary complex formation (4 and 18 h, respectively) remained constant for each cell line, independent of the LCV dose used (Figure 3a and b) . In both MCF-7 and H630 cells, the total amount of TS ternary complex formed was 1.2-to 2.6-fold higher in cells treated with the combination of 5-FU,LCV than in cells treated with 5-FU alone, depending on the dose and schedule used.
Analysis of total TS, TS complex andfree TS Owing to the differences in the time to maximal ternary complex formation in these two cell lines, we investigated the patterns of increase in TS ternary complex, free TS and the total TS enzyme in both cell lines using 0.1 and 10 gIM concentrations of LCV. In MCF-7 cells exposed to 5-FU (10JM) LCV (10IM). the total TS increased by up to 2.7-fold compared with the TS level in MCF-7 cells treated with LCV (IO M) alone depending on the schedule used ( Figure  4a ). This compared with a 1.4-fold increase in total TS when MCF-7 cells were exposed to 5-FU (10 IM) alone. The greatest increase in total TS was noted when 5-FU was delayed for 4h after the start of LCV (10JIM) exposure. While TS ternary complex formation was also maximal after 4 h. the amount of free TS in MCF-7 cells did not change significantly among the various time points of 5-FU delay for up to 24 h (Figure 4a) . A similar trend in intracellular TS levels was found in MCF-7 cells treated with 0.1 I M LCV and 10JM 5-FU. The total TS increased by up to 2.0-fold while the free TS remained unchanged (data not shown).
In NCI H630 cells exposed to 5-FU (10 ILM) and LCV (IO JiM), the TS total increased by up to 3.1-fold (Figure 4b ). whereas only a 1.6-fold increase in total TS was observed when H630 cells were exposed to 5-FU (IO M) alone. In contrast to MCF-7 cells, the total TS continued to increase up to an 18 h delay between the start of LCV and 5-FU exposure. The amount of free TS remained relatively unchanged in H630 cells whether 5-FU was given concurrent with LCV or delayed for up to 24 h (Figure 4b ). Similar patterns in TS protein levels were observed using 0.1 JIm LCV (data not shown).
Folate polvglutamation profile
The pattern of intracellular folate polyglutamation is an important determinant of intracellular folate retention and their affinity for TS. It is also an important determinant in ternary complex formation with TS and FdUMP. We examined the extent of polyglutamation of LCV to the higher polyglutamates (Glul-Glu,) at 4 and 18 h after the start of maximal when 5-FU was delayed for 4 h after LCV exposure. wkhereas in H630 cells TS complex was maximal after an 18 h 5-FU delay. The point of maximal ternary complex formation was similar for each LCV dose used in Total TS both cell lines. This time-dependent variation in maximal TS complex formation was reflective of the total intracellular TS level. In MCF-7 cells. total TS levels were maximal at the 4 h 5-FU delay time point, whereas in H630 cells the amount of Complex TS total intracellular TS continued to increase when cells were exposed to 5-FU for up to 18 h after LCV exposure. Since an increase in ternary complex formation paralleled the increase Free TS in total TS. the amount of intracellular free TS did not change in either cell line. These patterns in TS levels were independent of LCV dose. Thus. the level of intracellular free TS present at longer 5-FU delay time points was similar to that obtained by giving both drugs simultaneously. This suggests that the effect of LCV on enhanced ternary complex formation is present for up to 18 h after removal of the LCV, presumably because of the prolonged retention of folate polyglutamates (Table I) . The results also demonstrate that the combination of 5-+ Total TS FU LCV resulted in a 2-to 3-fold greater increase in total TS protein over that seen with 5-FU alone; moreover. the amount of total TS protein increased in proportion to LCV 4 Complex TS dose and depended on the delay in 5-FU exposure. This time-dependent increase in TS protein would appear to be a function of the rate of formation of higher folate polyglutamates. Induction of TS protein synthesis may be respono Free TS sible for the increased total TS protein and may be an important cellular response to 5-FU LCV, as has been previously described in cells treated with 5-FU alone (Chu et  24 al., 1993); however, this does not lead to increased free TS levels, as the majority of this newly synthesised TS becomes bound as ternary complex. (Houghton et al.. 1990 : Romanini et al., 1991 (Machover et al.. 1986; Erlichman et al., 1988; Petrelli et al.. 1989; Poon et al.. 1989; Valone et al.. 1989 ; Advanced Colorectal Cancer Meta-Analysis Project. 1992) . In order to achieve the target concentrations of LCV defined by preclinical investigations (1-1OI1M) clinical investigators have used a variety of doses and schedules of LCV. In patients. highdose LCV therapy (200-500 mg m-2) can achieve plasma levels of 10-501M, while low-dose regimens (20-50 mg m-2) result in reduced folate levels in the 1 JIm range (Trave et al.. 1989; Gerstner et al., 1991; Priest et al.. 1991; Machover et al.. 1992) . Differences in response to 5-FU, LCV combinations have been noted with regard to LCV dose in some studies. Patients on a North Central Cancer Tumor Group study were randomised to receive 370 mg m-with LCV 200mgm-2 day-' for 5 days every 4-5 weeks or 5-FU 425 mg m-2 plus LCV 20 mg m-' daily for 5 days every 4-5 weeks. Those patients who received low-dose LCV had a better response rate than those who received a high-dose; however, there was no difference in survival (Poon et al., 1989) . Patients on the low-dose arm received 15% more 5-FU, which may have accounted for some of the increase seen in response rate. Another study, by Petrelli et al. (1989) , compared 5-FU alone (500 mgm-) with identical doses of 5-FU with either low-dose LCV (25 mg m-) given as a 15mmn infusion or high-dose LCV (500 mgm--) given as a 2 h infusion. The response rate in the high-dose arm was significantly higher than in the 5-FU-only arm. The response rate between the low-dose LCV and 5-FU alone was not statistically different ). Thus. the data from these studies suggest that low-dose LCV may be as effective as high-dose LCV when using a repetitive dosing schedule (daily for 5 days). but not with a weekly schedule. in which case dose appears to be important. One possible explanation for this observation is that the effect of low-dose LCV on ternary complex formation persists for up to 24 h after LCV exposure. as demonstrated by this study. With daily doses of LCV. each dose would have an effect on ternary complex formation. in addition to the persistent effect of the previous dose. A similar phenomenon may not occur with a longer weekly interval.
In conclusion, these studies suggest that low-dose LCV 
